These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
9. Anti-lipopolysaccharide and anti-tumor necrosis factor/cachectin antibodies for the treatment of gram-negative bacteremia and septic shock. Calandra T; Baumgartner JD; Glauser MP Prog Clin Biol Res; 1991; 367():141-59. PubMed ID: 1924424 [TBL] [Abstract][Full Text] [Related]
10. Antibiotic-mediated release of endotoxin and the pathogenesis of gram-negative sepsis. Morrison DC Prog Clin Biol Res; 1998; 397():199-207. PubMed ID: 9575560 [TBL] [Abstract][Full Text] [Related]
11. Evaluation of teicoplanin's therapeutic efficacy in immunocompromised patients with staphylococcal sepsis. Orani A; Fossati M; Castelli N; Sala A J Chemother; 1989 Jul; 1(4 Suppl):716-9. PubMed ID: 16312605 [No Abstract] [Full Text] [Related]
12. Targeting endotoxin in the treatment of sepsis. Rachoin JS; Schorr CA; Dellinger RP Subcell Biochem; 2010; 53():323-38. PubMed ID: 20593274 [TBL] [Abstract][Full Text] [Related]
13. [Advances in the development of neutralizing therapies for sepsis]. Florencia Henning M; Garda H; Bakás L Medicina (B Aires); 2006; 66(3):263-73. PubMed ID: 16871917 [TBL] [Abstract][Full Text] [Related]
14. Molecular biology of endotoxin antagonism. Lazaron V; Dunn DL World J Surg; 2002 Jul; 26(7):790-8. PubMed ID: 11948366 [TBL] [Abstract][Full Text] [Related]
15. Lipoproteins/peptides are sepsis-inducing toxins from bacteria that can be neutralized by synthetic anti-endotoxin peptides. Martinez de Tejada G; Heinbockel L; Ferrer-Espada R; Heine H; Alexander C; Bárcena-Varela S; Goldmann T; Correa W; Wiesmüller KH; Gisch N; Sánchez-Gómez S; Fukuoka S; Schürholz T; Gutsmann T; Brandenburg K Sci Rep; 2015 Sep; 5():14292. PubMed ID: 26390973 [TBL] [Abstract][Full Text] [Related]
16. Risk factors and etiology of neonatal sepsis in Tikur Anbessa University Hospital, Ethiopia. Shitaye D; Asrat D; Woldeamanuel Y; Worku B Ethiop Med J; 2010 Jan; 48(1):11-21. PubMed ID: 20607993 [TBL] [Abstract][Full Text] [Related]
17. The role of monoclonal antibodies in the management of gram-negative sepsis. Experience with the E5 antibody. Gorelick KJ; Chmel H Infect Dis Clin North Am; 1991 Dec; 5(4):899-913. PubMed ID: 1783775 [TBL] [Abstract][Full Text] [Related]
18. Recent developments in our understanding of sepsis: evaluation of anti-endotoxin antibodies and biological response modifiers. Talan DA Ann Emerg Med; 1993 Dec; 22(12):1871-90. PubMed ID: 8239111 [TBL] [Abstract][Full Text] [Related]
19. Endotoxin-neutralizing peptides as gram-negative sepsis therapeutics. Wong KF; Luk JM Protein Pept Lett; 2009; 16(5):539-42. PubMed ID: 19442233 [TBL] [Abstract][Full Text] [Related]
20. Antibiotic induced endotoxin release and clinical sepsis: a review. Holzheimer RG J Chemother; 2001 Nov; 13 Spec No 1(1):159-72. PubMed ID: 11936361 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]